JFR, I'll agree, but after approval don't you suspect that many brokers will want to become associated with NWBO over time.
I believe that LP is well connected, but those connections are meaningless until success changes the way the investment public is looking at NWBO. The MM's may have largely been controlling what's happening up to now, but post approval I really don't believe they'll be able to keep the share price down and the short squeeze will be a thing of beauty for all who're long. Once the short position is largely cleared we'll be a very different company.
Many who've spoken with DI have been assured the news won't end when an approval is announced. I suspect that once we get that approval a month won't go by without some meaningful release will come out of the company, at least for awhile. Perhaps some things could be said before approval, but holding them until after may greatly increase their impact. Other things frankly are keyed to at least the initial approval, so that's when we'll start to get word of them.
I think we all know that the company will have many choices as to the direction they want to take after approval. They may have already decided, or they could be waiting. Personally I still believe that CRL could play a major role, but it's not impossible to do it completely without them. I suspect that CRL already knows what NWBO will be doing, but no one can say anything until the time is right and that could be dependent on acceptance of the EDEN unit as well. Of course if CRL is purely intended to support the US it could all be dependent on an FDA submission as well.
Gary
Bullish
